Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHALLENGE: Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma with Child-Pugh B
jRCTs031210355Phase 2Completed
- Sponsor
- Japan Oncology Network in Hepatobiliary and Pancreas
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Japan Oncology Network in Hepatobiliary and Pancreas. Primary endpoint: Severe adverse events. Started Dec 2021; status: completed.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCTs031210355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210355.